- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.01. | Soley secures $200M series C to push AML cell stress drug into clinic | ||
| 07.01. | Basilea pens collab with US biotech to develop new antifungal | ||
| 07.01. | GSK's 'functional cure' for hep B proves worth in phase 3 trials setting up approval push | ||
| 07.01. | Hutchmed heats up autoimmune race with phase 3 win, teeing up China filing | ||
| 06.01. | Boehringer continues kidney disease dealmaking run with $120M Variant Bio pact | ||
| 06.01. | Bright Minds shines with phase 2 win for anti-seizure serotonin receptor activator | ||
| 06.01. | Amgen stitches new acquisition worth up to $840M for UK biotech and its cancer programs | ||
| 06.01. | In Structure licensing deal, Roche commits $100M to shore up GLP-1 position | ||
| 06.01. | Arrowhead takes aim at obesity market with early data on dual gene silencing assets | ||
| 06.01. | Lilly returns to Nimbus with $1.3B deal to create new oral obesity drug | ||
| 06.01. | Alumis beams as pivotal data on Sotyktu rival drive stock surge | ||
| 06.01. | Instil's stock sinks after it clears out pipeline, hands 2 drugs back to ImmuneOnco | ||
| 06.01. | UK biotech eyes $1B deal to enable eye gene therapy to be delivered in doctors' offices | ||
| 05.01. | MetaVia weighs in with 9% loss as dual agonist enters the obesity ring | ||
| 05.01. | Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit | ||
| 05.01. | Aktis Oncology aims for $209M windfall from 1st biotech IPO of 2026 | ||
| 05.01. | Sanofi's latest autoimmune bispecific pact with AI biotech could reach $2.5B | ||
| 05.01. | Cash-strapped TME Pharma loses partner, prompting eye drug strategy rethink | ||
| 02.01. | NIH instability grows with exit of neuro director, leaving half of institutes under interim leadership | ||
| 02.01. | AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals | ||
| 02.01. | Neuro biotech Nido closes after phase 2 study fails to move needle in rare disease | ||
| 02.01. | J&J junks $1.2B eczema therapy while Genmab clears out cancer drug | ||
| 02.01. | Ultragenyx plans major cost-cutting push after flunking phase 3 brittle bone trials | ||
| 02.01. | Biohaven flunks phase 2 depression trial, adding to concerns for pivotal epilepsy readout | ||
| 23.12.25 | Windtree offloads cardio pipeline, Vaccinex secures $60M funding in continued holiday shopping spree |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.